Sunday 18 October 2026
Export EYPT’s income statement to Excel — free account
EyePoint, Inc.
EYPT Healthcare Biotechnology
EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024. In the quarter to June 2026, revenue fell 90.5%, EPS fell 28.2% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.00
0.14
−4.46%
Follow EYPT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
443.89 | 145.59 | 42.66 | 23.60 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.85) | (13.76) | (20.57) | (16.83) | |
P/B ratio |
7.44 | 4.81 | 4.37 | 4.99 | |
Price to Tangible BV |
8.51 | 5.29 | 4.69 | 5.57 | |
EV/Sales |
391.59 | 120.92 | 34.01 | 19.60 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.08) | (3.44) | (4.44) | (3.93) | |
EV/FCF |
(4.03) | (3.39) | (4.39) | (3.89) | |
Quick Ratio |
4.30 | 5.97 | 8.28 | 6.81 | |
Current Ratio |
4.50 | 6.66 | 8.88 | 7.18 | |
Net Debt/EBITDA |
1.86 | 2.55 | 4.34 | 3.27 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.02 | 0.08 | 0.15 | |
Operating CF/Net income |
0.66 | 0.95 | 0.96 | 0.99 | |
Capex/Depreciation |
(2.40) | 7.02 | 3.39 | 2.13 | |
Research and Development Expense of Revenue |
16,491.91% | 10,366.09% | 9,565.91% | 4,943.48% | |
Selling, General and Administrative Expense of Revenue |
2,815.19% | 2,190.52% | 1,837.80% | 1,502.69% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2,050.89% | 1,672.13% | 1,090.31% | 665.42% | |
Graham Net Nets |
0.10 | 0.17 | 0.20 | 0.16 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(26.15%) | (27.15%) | (17.30%) | (21.00%) | |
Free Cash Flow Yield |
(21.91%) | (24.48%) | (18.17%) | (21.38%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.72) | (0.94) | (0.89) | (0.85) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.73) | (0.95) | (0.90) | (0.86) | |
Cash per Share |
2.09 | 2.59 | 4.18 | 2.91 | |
Shareholders Equity per Share |
1.92 | 2.68 | 4.18 | 2.85 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.92 | 2.68 | 4.18 | 2.85 | |
Free Cash Flow |
(63.55) | (81.55) | (65.88) | (60.15) | |
Working Capital |
146.87 | 212.04 | 291.63 | 186.01 | |
Capital Expenditures |
(1.20) | (1.00) | (0.83) | (0.80) | |
Net Current Asset Value |
127.04 | 191.76 | 270.77 | 164.59 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
2.37 | 1.43 | 1.34 | 0.83 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.36 | 0.80 | 0.63 | 0.71 | |
Average Payables |
18.48 | 17.62 | 11.11 | 8.71 | |
Average Inventory |
2.28 | 1.69 | 2.06 | 2.46 | |
Average Assets |
264.67 | 325.39 | 391.23 | 276.31 | |
Average Common Equity |
206.21 | 264.43 | 321.31 | 209.46 |
Columns are period end dates